Psoriasis: risankizumab shows efficacy in SustaIMM phase 2/3 trial

  • Ohtsuki M & al.
  • J Dermatol
  • 25 Jun 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Risankizumab (Skyrizi) is associated with clinical improvement in Japanese patients with moderate to severe plaque psoriasis, according to results from the SustaIMM phase 2/3 trial.

Why this matters

  • Risankizumab, an interleukin 23 inhibitor, may represent a new treatment option for psoriasis.

Key results

  • At week 16, risankizumab was associated with a higher rate of ≥90% improvement in Psoriasis Area and Severity Index (PASI-90) compared with placebo (75.9% for 75 mg, 74.5% for 150 mg, 1.7% for placebo; P<.001 style="list-style-type:circle;">
  • Similar results were observed for static Physician Global Assessment score of clear/almost clear (86.2%, 92.7%, and 10.3%, respectively; P<.001 and pasi-100 respectively p>
  • At week 52, PASI-90 was achieved by 86.2% of patients in the risankizumab 75-mg group and 92.7% of patients in the risankizumab 150-mg group.
  • 52% of patients in the risankizumab 75-mg group, 56% of patients in the risankizumab 150-mg group, and 57% of patients in the placebo group experienced an adverse event during the first 16 weeks.
  • Study design

    • 171 patients were randomly assigned 2:2:1:1 to 75 mg risankizumab, 150 mg risankizumab, placebo with crossover to 75 mg risankizumab, or placebo with crossover to 150 mg risankizumab.
    • Funding: AbbVie; Boehringer Ingelheim.

    Limitations

    • Relatively small patient sample size.